ロード中...
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
Targeted therapies including the engineered afucosylated anti-CD20 monoclonal antibody obinutuzumab, Bruton’s tyrosine kinase inhibitor ibrutinib, and B-cell lymphoma protein 2 inhibitor venetoclax have demonstrated significant clinical activity in chronic lymphocytic leukemia (CLL) and, based on th...
保存先:
| 出版年: | Blood |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6182267/ https://ncbi.nlm.nih.gov/pubmed/30111609 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-05-853564 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|